SFEBES2016 ePoster Presentations (1) (116 abstracts)
Wrexham Maelor Hospital, Wrexham, UK.
A 36 year-old female presented with increasing headaches over the previous 8 months. She had seen in the neurology clinic recently and treated for migraines and cluster headache. She also had a history of depression. She had prodromal aura of visual disturbance including blurred vision and photophobia.
She was admitted following sudden onset of stabbing pain over the left eye along with nausea. All these symptoms were classic of her usual migraines. On admission to hospital there was no focal neurological deficit but she was noted to have palpable lymph nodes in her right groin and neck. A full body CT scan revealed widespread enlargement of lymph glands, enlarged spleen, along with an abnormal enhancing focus with soft tissue nodularity in the para-sellar and suprasellar region.
MRI of brain showed enlargement on the pituitary gland with displacement of the pituitary stalk. There was also an abnormal soft tissue focus in the right para-sellar region encroaching upon the sella. There was no evidence of involvement elsewhere in the brain. Baseline and dynamic pituitary function testing was normal.
Lymph node excision biopsy confirmed Hodgkins lymphoma of the nodular sclerosing type. Lumbar puncture was normal and bone marrow biopsy and trephine showed no evidence of lymphoma. She was diagnosed with stage IIIB Hodgkins lymphoma. The nature of the para-sellar mass was uncertain as cranial involvement in Hodgkins lymphoma usually occurs in the terminal phase of the disease.
The patient underwent chemotherapy with the ABVD regimen. A repeat MRI of the brain and pituitary after 2-months of chemotherapy showed a dramatic change with almost complete resolution of the para-sellar mass and normalization of the pituitary size. Repeated interval MRIs have been normal and the patient has remained in remission from her Hodgkins Lymphoma.
This case illustrates an unusual presentation of a para-sellar mass due to Hodgkins lymphoma and its response to chemotherapy.